Clene Inc. to Present at D. Boral Capital Global Conference in New York
TL;DR
Clene (NASDAQ: CLNN) to participate in D. Boral Capital Inaugural Global Conference, offering exclusive one-on-one meetings for potential investors.
Clene focuses on improving mitochondrial health and protecting neuronal function through their investigational therapy CNM-Au8® for neurodegenerative diseases.
Clene's work aims to enhance central nervous system cells' survival and function, potentially revolutionizing the treatment of neurodegenerative diseases for a better tomorrow.
Clene's participation in the conference showcases cutting-edge research in neurodegenerative disease treatment, providing hope for patients worldwide.
Found this article helpful?
Share it with your network and spread the knowledge!
Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company specializing in neurodegenerative disease research, will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City.
President and CEO Rob Etherington will be available for one-on-one meetings with investors and analysts from 9 a.m. to 3 p.m. ET. The conference provides an opportunity for the company to discuss its ongoing research into neurological conditions, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis.
The company's primary investigational therapy, CNM-Au8®, targets mitochondrial function and the NAD pathway while reducing oxidative stress. This innovative approach aims to improve central nervous system cells' survival and function, potentially offering new treatment options for patients with challenging neurological disorders.
For investors and healthcare professionals, the conference represents a critical opportunity to gain insights into Clene's research progress and potential breakthrough treatments in neurodegenerative disease management.
Curated from InvestorBrandNetwork (IBN)
